RO5285119 + risperidone

RO5285119 + risperidone is an **experimental combination** of two pharmaceutical agents: - **RO5285119** is an investigational, selective **glycine transporter type 1 (GlyT1) inhibitor** developed by Roche. Its presumed mechanism involves increasing synaptic glycine levels to modulate NMDA receptor function, potentially targeting negative and cognitive symptoms of psychiatric disorders such as schizophrenia. - **Risperidone** is an FDA-approved, atypical antipsychotic primarily acting as a **dopamine D2 and serotonin 5-HT2A receptor antagonist**. It is indicated for schizophrenia, bipolar mania, and irritability associated with autism. This combination was evaluated in completed phase 1 trials to study pharmacokinetics and possible interactions in healthy volunteers. No marketed products containing this combination are approved. The experimental rationale appears to be testing potential cognitive or negative symptom benefits in schizophrenia or related disorders.